Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 8/20 | 0.59 |
| ▸ | HTR1A | P08908 | 6/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.53 |
| ▸ | HTR3B | O95264 | 3/20 | 0.53 |
| ▸ | HTR3A | P46098 | 3/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | HTR5A | P47898 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6650883 | 0.88 | HTR7 (0.59) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL4915273 | 0.83 | RPS6KA3 (0.54) | HTR7HTR1ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7591669 | 0.81 | HTR7 (0.67) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL6650889 | 0.81 | HTR7 (0.58) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL20708495 | 0.79 | ACVR1 (0.52) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL478208 | 0.78 | ADRB1 (0.57) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL24989048 | 0.78 | HTR7 (0.55) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL4890361 | 0.76 | RAD52 (0.43) | HTR2AHTR2CCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4885161 | 0.76 | RAD52 (0.43) | HTR2AHTR2CCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4885558 | 0.76 | RAD52 (0.43) | HTR2AHTR2CCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | claimed |
| CN-101084205-A | N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto | ARENA PHARM INC (US) | 2007-12-05 | — | — | CN | claimed |
| EP-1828156-A2 | N-BIARYL AND N-ARYLHETEROARYL PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006065600-A2 | N-BIARYL AND N-ARYLHETEROARYL PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | claimed |
| US-20210052600-A1 | THERAPEUTIC AGENTS FOR STRESS URINARY INCONTINENCE AND INCOTINENCE OF FECES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3733204-A1 | THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| CN-101084205-A | N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto | ARENA PHARM INC (US) | 2007-12-05 | — | — | CN | disclosed |
| EP-1828156-A2 | N-BIARYL AND N-ARYLHETEROARYL PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006065600-A2 | N-BIARYL AND N-ARYLHETEROARYL PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | HTR2C, HTR2A, HTR5A | HTR7 10/4885HTR1A 9/4885ADRB1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.